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SUMMARY – Th ere is limited evidence showing that elevated arterial blood pressure in surgical 
patients may be associated with increased perioperative risk; however, cardiovascular instability fre-
quently occurs during anesthesia. Th e most commonly used anesthetic agents, both intravenous and 
inhalation ones, produce a decrease in arterial blood pressure. Magnesium, acting as a natural calcium-
channel blocker, induces direct and indirect vasodilatation, thus playing a role in the treatment of arte-
rial hypertension. In this research, we assessed the eff ects of magnesium sulfate on cardiovascular 
stability in patients undergoing diverse planned surgical procedures (abdominal, orthopedic, urology) 
under general balanced anesthesia, who were diagnosed with arterial hypertension grade 1 and 2. Th e 
research encompassed 100 patients of both sexes, aged from 20 to 65. Immediately before induction 
of anesthesia with propofol, the patients in the experimental group (50 study subjects) received 30 mg/
kg bolus dose and magnesium sulfate infusion at 10 mg/kg/h, whereas the subjects in the control 
group (50 patients) were administered normal saline. Anesthesia was achieved and maintained with 
sevofl urane, fentanyl and rocuronium. Th e hemodynamic variables of mean arterial pressure and heart 
rate were measured every fi ve minutes, starting immediately before magnesium infusion. Statistical 
analysis of the categorized values of mean arterial pressure and heart rate revealed a statistically sig-
nifi cant between-group diff erence at 60th and 90th minute of anesthesia. In conclusion, magnesium 
sulfate as an adjuvant to anesthesia in patients with arterial hypertension reduces hemodynamic 
changes during anesthesia.
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Introduction
Although recent developments in technical and 
procedural aspects of anesthesiology have allowed sub-
stantial advancement of surgery, unavoidable anesthe-
sia-related risks such as perioperative morbidity and 
mortality still remain a problem even in the 21st cen-
tury1. Accordingly, anesthesiologist plays an important 
role as a perioperative physician responsible for preop-
erative assessment, patient preparation, planning and 
selection of optimal anesthetic technique, and appro-
priate pharmacological agents.
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Preoperative indicators of cardiovascular risk in 
non-cardiac surgery include ischemic heart disease, 
congestive heart failure, cerebrovascular disease, pre-
operative insulin therapy, and preoperative serum cre-
atinine levels above 150 μmol/L2. Surgical factors af-
fecting cardiac risks are strongly related to the urgency, 
extent, type and duration of the procedure itself3.
It is believed that 15% of patients presenting for 
surgical procedures that require anesthesia suff er from 
arterial hypertension. Cardiovascular instability during 
anesthesia is more prevalent in these patients. Arterial 
hypertension associated with organ failure (ischemic 
heart disease, heart failure, renal failure) substantially 
increases the probability of perioperative cardiovascu-
lar complications. Establishing the type of hyperten-
sion, i.e. whether primary (essential) or secondary, is of 
great importance for further procedure. Conditions 
such as pheochromocytoma, hyperaldosteronism and 
renovascular hypertension require specifi c individual 
anesthesiologic approach4.
According to the guidelines of the European Soci-
ety of Hypertension (ESH) and European Society of 
Cardiology (ESC), blood pressure is defi ned and clas-
sifi ed as follows: optimal (systolic <120 mm Hg, dia-
stolic <80 mm Hg); normal (systolic 120-129 and/or 
diastolic 80-84); high normal (systolic 130-139 and/or 
diastolic 85-89); grade 1 hypertension (systolic 140-
159 and/or diastolic 90-99); grade 2 hypertension 
(systolic 160-179 and/or diastolic 100-109); grade 3 
hypertension (systolic >180 and/or diastolic >110); 
and isolated systolic hypertension (systolic >140, dia-
stolic <90 mm Hg)5.
Grade 1 and 2 hypertension by itself is not consid-
ered a risk factor for the occurrence of perioperative 
cardiovascular complications. In patients with grade 3 
hypertension associated with apparent heart or kidney 
failure, the surgery should be delayed until reestablish-
ment of normal arterial blood pressure and etiologic 
examination. If the surgery must be performed with-
out delay, invasive intraoperative monitoring of arterial 
blood pressure should be provided while limiting os-
cillations of the mean arterial blood pressure to 20% of 
baseline values4.
An optimal strategy that would maximally reduce 
the risks of perioperative cardiovascular complications 
implicates comprehensive preoperative cardiac evalua-
tion of the patient along with appropriate pharmaco-
logical treatment regimen3. Patients suff ering from 
arterial hypertension are frequently exposed to extreme 
hypotension after induction of anesthesia, as well as to 
hypertensive stress-response to laryngoscopy and intu-
bation, surgical incision and extubation. Postopera-
tively, inadequate pain relief can induce hypertensive 
response in such patients. Hypertensive episodes are 
often associated with arrhythmia and myocardial isch-
emia. Hypo- as well as hypertension can result in cere-
brovascular complications6.
Magnesium is of vital importance for human body. 
Th e majority of magnesium is absorbed in the small 
intestine. Kidneys play an important role in maintain-
ing magnesium balance within the body. Administra-
tion of diuretics substantially increases magnesium 
excretion. Th e metabolism of magnesium is regulated 
through the action of a variety of hormones. Parathy-
roid hormone upregulates renal excretion of magne-
sium and decreases its intestinal absorption. Mineralo-
corticoids (aldosterone), thyroid hormones and insulin 
are responsible for increased renal excretion of magne-
sium, whereas adrenaline is associated with elevation 
of plasma magnesium levels. Increased serum magne-
sium concentration (hypermagnesemia) can occur in 
chronic infectious diseases, diabetic ketoacidosis, Ad-
dison’s disease, atherosclerosis, and particularly in 
chronic renal insuffi  ciency. Decreased serum magne-
sium level (hypomagnesemia) is often associated with 
enduring diarrhea, prolonged diuretic therapy, malab-
sorption syndrome, hyperaldosteronism and alcohol-
ism. Hypomagnesemia is a common event in hypoka-
lemic patients. Ionized free magnesium in serum is of 
crucial biological importance for mediating cellular 
ion channels and transport mechanisms. Magnesium 
plays a role in controlling calcium entry into the cells, 
thus aff ecting the cardiac smooth muscle tone, i.e. the 
tone of vascular smooth muscles7.
Magnesium is considered the fourth most common 
cation within the whole of the human body and the 
second most important intracellular cation. It is a co-
factor in the activation of a whole range of enzymes 
involved in biochemical reactions of protein synthesis. 
Magnesium manifests antinociceptive eff ects as a 
competitive antagonist of N-methyl-D-aspartate re-
ceptors. Competing with calcium ions, magnesium in-
hibits the release of presynaptic acetylcholine, thus 
enhancing the action of neuromuscular blocking 
agents. Magnesium sulfate depresses the central ner-
vous system and reduces anesthetic requirements8.
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Magnesium is regarded as a natural physiologic 
calcium antagonist. Patients subjected to major surgi-
cal procedure without magnesium supplementation 
are exposed to an increased risk of hypomagnesemia 
during the early postoperative period9. Magnesium is 
also used as an eff ective antiarrhythmic agent10. Some 
in vitro studies demonstrated that magnesium pre-
vented catecholamine release from the adrenal medul-
la and adrenergic terminals, and produced coronary 
vasodilatation11. Ryu et al. demonstrated that the ef-
fects of magnesium sulfate in providing adequately 
controlled hypotension in patients undergoing ear sur-
gery were the same as those of remifentanil12.
Magnesium sulfate is applicable in therapy of hy-
pokalemia, asthmatic attack and for protecting the 
heart muscle following ischemia13. Some recent stud-
ies strongly suggest the anti-infl ammatory eff ects of 
magnesium sulfate14.
Th e concentration of total magnesium in the serum 
of an adult person ranges between 0.65 and 1.05 mmol/
L7. Magnesium preparations are usually well tolerated 
even if administered at large doses. In healthy individu-
als, plasma levels of magnesium ranging within the in-
terval of 2-3.5 mmol/L are considered acceptable15.
Th e aim of this research was to establish the eff ects 
of magnesium sulfate on cardiovascular stability in pa-
tients suff ering from arterial hypertension, who were 
subjected to non-cardiac surgery (elective abdominal, 
orthopedic and urology surgical procedures) under 
general balanced anesthesia.
Patients and Methods
In this double blind, prospective, randomized and 
controlled clinical trial, we assessed the eff ects of mag-
nesium sulfate on cardiovascular stability in patients 
undergoing diverse planned surgical procedures (ab-
dominal, orthopedic, urology) under general balanced 
anesthesia, who were diagnosed with grade 1 and 2 arte-
rial hypertension. Th e research encompassed 100 pa-
tients of both sexes, aged from 20 to 65. Immediately 
before the induction of anesthesia with propofol (2 mg/
kg intravenously), the patients received 30 mg/kg bolus 
dose and magnesium sulfate infusion at 10 mg/kg/h (M 
group, n=50 patients) or saline placebo (K group, n=50 
patients). Anesthesia was achieved and maintained with 
sevofl urane (1-3 vol%), fentanyl (5 μg/kg) and rocuroni-
um (0.15 mg/kg every 30 minutes).
Pregnant women, patients with organ failure, pa-
tients with elevated potassium and magnesium levels, 
patients on calcium channel blocker therapy, and pa-
tients with AV block, myasthenia gravis or porphyria 
were not included in the research. Furthermore, pa-
tients suff ering massive intraoperative blood loss and 
those treated intraoperatively with antihypertensive 
drugs, antiarrhythmics or diuretics were excluded from 
the study.
Th e hemodynamic parameters of the mean arterial 
pressure (MAP) and heart rate (HR) were monitored 
and recorded every fi ve minutes. Baseline MAP had 
been measured before magnesium intravenous bolus 
was administered to the patient. Arterial blood pres-
sure was measured noninvasively (Datex-Ohmeda S/5 
2008).
All subjects gave their informed consent for par-
ticipation in this study, approved by the local Ethics 
Committee.
Diff erences between the investigated groups were 
evaluated using Pearson c2-test, Fisher exact test, and 
Wilcoxon rank sum test (Mann-Whitney). All hy-
potheses were tested at the level of statistical signifi -
cance of 0.05.
Results
Th e study encompassed 100 patients, 49 males and 
51 females. Pearson c2-test found no statistically sig-
nifi cant gender-related diff erences between the groups 
(c2=0.04, df=1, p=0.84145, p>0.05). Th e mean age of 
the group K and M patients was 57.1±7.96 and 
56.32±7.89 years, respectively. Mann-Whitney test 
demonstrated no statistically signifi cant age diff er-
ences (W=1303, p=0.71671, p>0.05). Out of 100 pa-
tients included in the study, 53 were categorized as 
American Society of Anesthesiologists (ASA) class II, 
whereas 47 were classifi ed as ASA III. Pearson c2-test 
demonstrated no statistically signifi cant diff erences 
according to ASA status (c2=1.004, df=1, p=0.31644, 
p>0.05). All patients included in this study suff ered 
from arterial hypertension. Out of 100 participating 
patients, 47 had grade I hypertension, whereas 53 pa-
tients had grade II hypertension. Pearson c2-test yield-
ed no statistically signifi cant between-group diff er-
ences according to the grade of arterial hypertension 
(c2=0.04, df=1, p=0.8412, p>0.05). Th e groups of par-
ticipants were homogeneous, thus statistical analysis is 
considered representative.
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Preoperative serum levels of magnesium ranged 
from 0.42 to 0.99 mmol/L in group K and from 0.56 
to 1.06 mmol/L in group M (Table 1). Postoperative 
serum magnesium values ranged from 0.4 to 0.9 
mmol/L and from 0.75 to 3.51 mmol/L in group K 
and M, respectively (Table 2).
Intravenous administration of magnesium sulfate 
bolus dose (30 mg/kg) resulted in MAP decrease in 
the majority of participants. After induction in anes-
thesia, patients from both groups manifested MAP 
decrease; however, diff erences between the groups 
were not statistically signifi cant. An increase in MAP 
values was recorded after endotracheal intubation in 
both groups, at a rate of 21% in group K and 18% in 
group M. In the majority of our patients, endotracheal 
intubation resulted in HR increase. Median HR in-
crease as related to baseline values was 33% and 26% in 
groups K and M, respectively. Statistical analysis of 
categorized values of MAP and HR yielded a statisti-
cally signifi cant between-group diff erence at 60th and 
90th minute of anesthesia. MAP values were within the 
range of hemodynamic stability (-20% to 20% decline 
from baseline values) in 21 (42%) group K patients and 
38 (76%) group M patients (Fig. 1). HR values were 
within the interval from -30% to 30% decline from 
baseline values in 26 (52%) group K patients and 37 
(74%) group M patients (Fig. 2).
According to minimum MAP values, it is apparent 
that the highest average drop was recorded among 
participants from group K with arterial hypertension 
grade 2. Diff erences between the group K arterial hy-
pertension grade 2 and group M arterial hypertension 
grade 2 subgroups (K HTA 2 and M HTA 2) were 
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statistically signifi cant (Mann-Whitney pair test, 
W=221, p=0.02033, p<0.05). Th e participants suff er-
ing from grade 2 arterial hypertension who were ad-
ministered magnesium sulfate manifested a signifi -
cantly lower MAP drop (Fig. 3).
Th e median extubation time after cessation of in-
halation anesthetic was 7.8±3.33 minutes in group K 
and 7.1±2.96 minutes in group M. Th is extubation 
time diff erence was not statistically signifi cant (Mann-
Whitney test, W=1395, p=0.31108, p>0.05). Th e mean 
pain intensity during the immediate postoperative pe-
riod was assessed using the numerical point scale, 
which yielded 5.58±2.89 points in group K and 5.02±
2.35 in group M. With respect to this parameter, there 
were no statistically signifi cant diff erences between the 
groups (Mann-Whitney test, W=1401.5, p=0.28882, 
p>0.05).
Discussion
In our research, statistical analysis of categorized 
MAP values at diff erent time intervals revealed a sta-
tistically signifi cant diff erence between the groups in 
the 60th minute of anesthesia. At 60th minute of anes-
thesia, there were no patients with hypertension (pa-
tients manifesting MAP increase by more than 20% as 
compared with baseline values) in group M. Th e data 
obtained data clearly showed that group M patients 
manifested better hemodynamic stability than those 
from group K at 60th minute of anesthesia. Th e HR 
values at 90th minute of anesthesia ranged from -30% 
to +30% from baseline values in 52% of group K pa-
tients and 74% of group M patients.
So far, the dosage of magnesium sulfate has been 
highly variable. Usmani et al. administered magnesium 
sulfate bolus 50 mg/kg along with continuous infusion 
at 15 mg/kg/h for pain control16. In the study by Sey-
han et al., continuous infusion of magnesium sulfate at 
a dose of 10 mg/kg/h was suffi  cient to substantially 
reduce the doses of intraoperative anesthetics and neu-
romuscular blockers, as well as postoperative analge-
sics17. Niruthisard et al. administered magnesium sul-
fate infusion to attenuate hypertensive crisis during 
pheochromocytoma resection in a patient with multi-
ple endocrine neoplasia type IIa18.
A number of studies demonstrated that the ad-
ministration of magnesium sulfate during anesthesia 
substantially aff ected the hemodynamic parameters. 
Elsharnouby and Elsharnouby applied magnesium 
sulfate (bolus dose 40 mg/kg, along with i.v. infusion at 
15 mg/kg/h) as a technique of hypotensive anesthesia 
in endoscopic sinus surgery. Th e authors report statis-
tically signifi cantly lower MAP values in patients hav-
ing received magnesium19.
Altan et al. compared the eff ects of magnesium sul-
fate and clonidine on hemodynamic parameters dur-
ing anesthesia and surgical procedure. MAP values 
recorded in patients receiving clonidine were signifi -
cantly lower at all time intervals; however, the diff er-
ence between the groups was not statistically signifi -
cant10.
Magnesium sulfate was used to prevent fl uctuation 
in arterial blood pressure during surgery for catechol-
amine-active glomus tumors in two patients. In one 
patient, sodium nitroprusside failed to provide  ade-
quate hemodynamic stability, which was established 
after the administration of magnesium sulfate. In the 
second patient, hemodynamic stability was success-
fully managed using magnesium sulfate as a single 
agent20.
Magnesium sulfate proved eff ective in patients with 
subarachnoid hemorrhage due to ruptured aneurysm 
of cerebral vessels21.
K HTA 1 = patients with arterial hypertension grade 1 receiving 
saline placebo; K HTA 2 = patients with arterial hypertension grade 
2 receiving saline placebo; M HTA 1 = patients with arterial hyper-
tension grade 1 receiving 30 mg/kg bolus dose and magnesium 
 sulfate infusion at 10 mg/kg/h; M HTA 2 = patients with arterial 
hypertension grade 2 receiving 30 mg/kg bolus dose and magne-
sium sulfate infusion at 10 mg/kg/h
Fig. 3. Lowest mean arterial pressure (MAP) compared 





Group K HTA 1
Group K HTA 2
Group M HTA 1
Group M HTA 2
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In the present study, cortisol, vasopressin and cate-
cholamine plasma levels were not analyzed, but the 
interaction of magnesium sulfate and vasopressin is 
well known because hypersecretion of antidiuretic 
hormone (vasopressin) results in hypomagnesemia. 
High concentrations of antidiuretic hormone also 
caused vasoconstriction and consequential increase of 
blood pressure. Application of magnesium sulfate re-
duces the eff ects of hormone stress response during 
surgery22,23.
Ryu et al. demonstrated the eff ects of magnesium 
sulfate in providing adequately controlled hypotension 
to be the same as those of remifentanil. However, post-
extubation MAP and HR values were higher in par-
ticipants administered remifentanil12.
Th e question, whether magnesium sulfate can ac-
tually provide hemodynamic stability during anesthe-
sia and under which dosage regimen, requires further 
research in order to be answered.
In conclusion, magnesium sulfate as an adjuvant 
to anesthesia in patients with arterial hypertension re-
duces hemodynamic changes during anesthesia.
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Sažetak
MAGNEZIJ SULFAT KAO ADJUVANS U ANESTEZIJI 
KOD BOLESNIKA S POVIŠENIM KRVNIM TLAKOM
S. Vicković, M. Pjević, A. Uvelin, D. Pap, D. Nikolić i I. Lalić
Postoje određeni dokazi koji ukazuju na postojanje povišenog perioperacijskog rizika kod kirurških bolesnika s povišenim 
arterijskim tlakom, a kardiocirkulacijska nestabilnost je česta pojava tijekom anestezije. Najčešće upotrebljavani intravenski i 
inhalacijski anestetici izazivaju snižavanje arterijskog tlaka. Magnezij kao prirodni blokator kalcijevih kanala izaziva vazodi-
lataciju te može imati ulogu u terapiji hipertenzije. U istraživanju su ispitani učinci magnezij sulfata na kardiocirkulacijsku 
stabilnost kod bolesnika s hipertenzijom prvog i drugog stupnja koji su podvrgnuti različitim elektivnim operacijskim zahva-
tima (abdominalna, ortopedska kirurgija, urologija) u općoj balansiranoj anesteziji. Studija je obuhvatila sto bolesnika oba 
spola u dobi od 20 do 65 godina. Neposredno prije intravenskog uvoda u opću anesteziju propofolom bolesnici u eksperi-
mentalnoj skupini dobili su magnezij sulfat u dozi od 30 mg/kg intravenski, a zatim je infuzija magnezij sulfata nastavljena 
po stopi od 10 mg/kg/h, dok su bolesnici u kontrolnoj skupini dobili 0,9%-tnu otopinu natrij klorida. Anestezija se održa vala 
primjenom sevofl urana i fentanila, a mišićna relaksacija primjenom rokuronija. Hemodinamski parametri, srednji arterijski 
tlak i srčana frekvencija mjereni su svakih 5 minuta, počevši neposredno prije infuzije magnezij sulfata. Statistička analiza 
pokazala je statistički značajnu razliku između eksperimentalne i kontrolne skupine u vrijednostima srednjeg arterijskog 
tlaka i srčane frekvencije u 60. i 90. minuti anestezije. Magnezij sulfat kao adjuvans kod bolesnika s hipertenzijom smanjuje 
hemodinamske promjene tijekom anestezije.
Ključne riječi: Magnezijev sulfat; Hipertenzija; Hemo dinamika; Srčana frekvencija; Adjuvansi, farmakološki; Anestezija
